Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

SIMPLE SUMMARY: Considering the favorable overall safety profile of trastuzumab emtansine (T-DM1), the low expected rate of cardiotoxicity, and the synergistic effect of anthracyclines with Human Epidermal Growth Factor Receptor 2 (HER2)-targeting agents, it is hypothesized that T-DM1 may be safely...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Miranda, Elena, Pérez-García, José Manuel, Di Cosimo, Serena, Brain, Etienne, Ravnik, Maja, Escrivá-de-Romaní, Santiago, Vidal, Maria, Gligorov, Joseph, Borštnar, Simona, Calabuig, Laura, Sampayo-Cordero, Miguel, Malfettone, Andrea, Llombart-Cussac, Antonio, Suter, Thomas M., Cortés, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760511/
https://www.ncbi.nlm.nih.gov/pubmed/33255658
http://dx.doi.org/10.3390/cancers12123509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760511/
https://www.ncbi.nlm.nih.gov/pubmed/33255658
http://dx.doi.org/10.3390/cancers12123509

Ejemplares similares